Buprenorphine Market is Estimated to Witness High Growth Owing to Increase in Opioid Addiction Treatment
Buprenorphine is a partial opioid agonist used to treat opioid addiction. It works by occupying the opioid receptors in the brain to prevent opioid withdrawal symptoms and reduce cravings. Buprenorphine is available as sublingual tablets and films that are placed under the tongue for absorption. It provides an alternative to methadone for medication-assisted treatment of opioid use disorder.
The global buprenorphine market is estimated to be valued at US$ 5.52 Billion in 2023 and is expected to exhibit a CAGR of 14.9% during the forecast period (2023-2030).
Key Takeaways
Key players operating in the buprenorphine market are AmSurg Corp., HCA Holdings, Inc., Tenet Healthcare, Surgical Care Affiliates, Inc., Surgery Partners, Ambulatory Surgical Centers of America, Heathway Medical Group, Community Health Systems, Inc., and Vision Group Holdings.
The increasing incidence of opioid addiction due to rising availability and abuse of prescription opioids and heroin presents a major growth opportunity for players in the Buprenorphine Market Trend. Technological advancements include the development of sublingual tablets and films with improved bioavailability and tamper-resistant formulations to curb misuse and diversion.
Market drivers
The primary driver for the growth of the buprenorphine market is the rising prevalence of opioid use disorder due to increasing prescription of opioid painkillers. It is estimated that over 2 million Americans suffer from prescription opioid and heroin addiction. Buprenorphine is one of the preferred medications for opioid addiction treatment due to its effectiveness and safety. The availability of generic versions of buprenorphine drugs has also increased its affordability and adoption rate. Stringent regulations supporting medication-assisted treatment using buprenorphine and naloxone combinations will further aid the expansion of the market over the forecast period.
Current challenges in Buprenorphine Market
The buprenorphine market has been witnessing some major challenges in recent times. One of the key issues has been the misuse and abuse of the drug. Since it is a powerful opioid, it has addiction potential if not used as prescribed. This has led regulatory authorities to impose stricter controls on its supply and availability. However, limiting access can affect patients who are dependent and undergoing treatment. Another challenge is the lack of guidelines on using buprenorphine for long-term treatment and management of addiction. More research is required to standardize protocols. On the production side, manufacturing complexities and costly manufacturing processes are restricting capacity expansion by players. Sourcing raw materials also remains a major cost driver. Overall compliance with regulations and supply chain issues need to be addressed to ensure smooth functioning.
SWOT Analysis
Strength: High efficacy rates in treating opioid dependence. Can be administered easily through films/tablets.
Weakness: Abuse potential if not used correctly. Strict regulations increase supply side challenges.
Opportunity: Expanding applications in pain management. Growing need for effective addiction treatment presents market potential.
Threats: Presence of alternative drug therapies. Stringent regulatory approvals delay product launches.
In terms of geographical concentration, North America dominates the global Buprenorphine Market Regional Analysis holding the largest share, both in terms of value and volume. Factors such as increasing opioid addiction and high adoption of drug therapy drives the regional market. Within North America, the US accounts for the major revenue share owing to the rising prevalence of prescription opioid abuse disorders. Europe follows North America in the overall buprenorphine industry, led by countries such as Germany and United Kingdom.
In the coming years, the Asia Pacific region is anticipated to witness the fastest growth in the global buprenorphine market supported by factors such as growing awareness about opioid dependence treatment across developing nations. Furthermore, the presence of a large patient pool coupled with improving access to innovative therapies also drives the regional market. Countries including China, India, Japan and Australia are expected to contribute significantly to the overall Asia Pacific buprenorphine sector during the forecast period.
Discover the Report for More Insights, Tailored to Your Language:
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment